MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Duration of rimabotulinumtoxinB action in the treatment of adult sialorrhea

S. Isaacson, M. Lew, F. Pagan, R. Pahwa, D. Chary, T. Clinch (Boca Raton, FL, USA)

Meeting: 2019 International Congress

Abstract Number: 114

Keywords: Botulinum toxin: Clinical applications: other, Sialorrhea

Session Information

Date: Monday, September 23, 2019

Session Title: Clinical Trials, Pharmacology and Treatment

Session Time: 1:45pm-3:15pm

Location: Agora 3 West, Level 3

Objective: To assess the duration of rimabotulinumtoxinB action in the management of sialorrhea.

Background: In neurological disorders, sialorrhea (drooling) is both prevalent and problematic. Local injections of botulinum toxin-B (BoNT-B) into the parotid and submandibular glands reduce saliva production, however patients require regular, repeated injections for maintained effectiveness. The standard reinjection schema is set at 12 weeks; however, it is important to understand the duration of action to ensure full symptom coverage over a treatment cycle.

Method: This was a double-blind, placebo-controlled study (NCT01994109). Adult subjects with Parkinson’s disease, amyotrophic lateral sclerosis, medication-induced, stroke and other disorders were randomized (1:1:1) to receive rimabotulinumtoxinB 2500U vs 3500U vs placebo. The last scheduled visit/time of reinjection was flexibly scheduled as 13 ±2 weeks. This post-hoc analysis evaluated the duration of action in those patients who responded (as defined by a 25% reduction in Unstimulated Salivary Flow Rate [USFR]) at peak effect (4 weeks).

Results: Of the 176 patients who completed the double-blind phase, 52/63 (82.5 %) in the 2500U group, 52/64 (81.3%) in the 3500U group and 18/57 (31.6%) in the placebo group were responders at peak effect. The proportion of responding patients (placebo vs. 2500U vs. 3500U) who went on to have their next injection in the open-label phase was 33% vs. 10% vs. 15% at ≤12 weeks; 60% vs. 74% vs. 52% at >12-≤14 weeks; and 7% vs. 16% vs. 33% at >14 weeks.

Conclusion: RimabotulinumtoxinB provided effective treatment for sialorrhea over the duration of the treatment cycle. Most patients had a treatment interval that was longer than the standard 12 weeks (78% had an injection at 13 weeks or later) and a third of patients on the 3500U dose had an interval of more than 14 weeks.

To cite this abstract in AMA style:

S. Isaacson, M. Lew, F. Pagan, R. Pahwa, D. Chary, T. Clinch. Duration of rimabotulinumtoxinB action in the treatment of adult sialorrhea [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/duration-of-rimabotulinumtoxinb-action-in-the-treatment-of-adult-sialorrhea/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/duration-of-rimabotulinumtoxinb-action-in-the-treatment-of-adult-sialorrhea/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley